News & events Upcoming events Oct 11, 2023 - Oct 13, 2023 ECTRIMS 2023 - 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Milano, Italy More info and meet us there Oct 11, 2023 - Oct 13, 2023 JFBM 2023 (Journées Francophones de Biologie Médicale) Antibes, Juan-les-Pins, France More info and meet us there Oct 12, 2023 - Oct 13, 2023 DGKL 2023 - Laboratoriumsmedizin in Zeiten der Transformation Mannheim, Germany More info and meet us there See all upcoming events Latest news Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Load More
Oct 11, 2023 - Oct 13, 2023 ECTRIMS 2023 - 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Milano, Italy More info and meet us there
Oct 11, 2023 - Oct 13, 2023 JFBM 2023 (Journées Francophones de Biologie Médicale) Antibes, Juan-les-Pins, France More info and meet us there
Oct 12, 2023 - Oct 13, 2023 DGKL 2023 - Laboratoriumsmedizin in Zeiten der Transformation Mannheim, Germany More info and meet us there
Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more
Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more
May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more
Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more
Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more
Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
